MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery
Authors:
- Piotr KalinowskiPKPiotr Kalinowski
- Wiktor SmykWSWiktor Smyk
- Małgorzata NowosadMNMałgorzata Nowosad
- Rafał PaluszkiewiczRPRafał Paluszkiewicz
- Łukasz MichałowskiŁMŁukasz Michałowski
- Bogna Ziarkiewicz-WróblewskaBZBogna Ziarkiewicz-Wróblewska
- Susanne N. WeberSWSusanne N. Weber
- Piotr MilkiewiczPMPiotr Milkiewicz
- Frank LammertFLFrank Lammert
- Krzysztof ZieniewiczKZKrzysztof Zieniewicz
- Marcin KrawczykMKMarcin Krawczyk
Open Access
- 13 December 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15825
Abstract
The severity of hepatic steatosis is modulated by genetic variants, such as patatin-like phospholipase domain containing 3 (PNPLA3) rs738409, transmembrane 6 superfamily member 2 (TM6SF2) rs58542926, and membrane-bound O-acyltransferase domain containing 7 (MBOAT7) rs641738. Recently, mitochondrial amidoxime reducing component 1 (MTARC1) rs2642438 and hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) rs72613567 polymorphisms were shown to have protective effects on liver diseases. Here, we evaluate these variants in patients undergoing bariatric surgery. A total of 165 patients who underwent laparoscopic sleeve gastrectomy and intraoperative liver biopsies and 314 controls were prospectively recruited. Genotyping was performed using TaqMan assays. Overall, 70.3% of operated patients presented with hepatic steatosis. NASH (non-alcoholic steatohepatitis) was detected in 28.5% of patients; none had cirrhosis. The increment of liver fibrosis stage was associated with decreasing frequency of the MTARC1 minor allele (p = 0.03). In multivariate analysis MTARC1 was an independent protective factor against fibrosis ≥ 1b (OR = 0.52, p = 0.03) and ≥ 1c (OR = 0.51, p = 0.04). The PNPLA3 risk allele was associated with increased hepatic steatosis, fibrosis, and NASH (OR = 2.22, p = 0.04). The HSD17B13 polymorphism was protective against liver injury as reflected by lower AST (p = 0.04) and ALT (p = 0.03) activities. The TM6SF2 polymorphism was associated with increased ALT (p = 0.04). In conclusion, hepatic steatosis is common among patients scheduled for bariatric surgery, but the MTARC1 and HSD17B13 polymorphisms lower liver injury in these individuals.Keywords
This publication has 37 references indexed in Scilit:
- PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cellsHuman Molecular Genetics, 2014
- Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2014
- Interdisciplinary European Guidelines on Metabolic and Bariatric SurgeryObesity Facts, 2013
- PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function?Clinics and Research in Hepatology and Gastroenterology, 2013
- FAT SIGNALS - Lipases and Lipolysis in Lipid Metabolism and SignalingCell Metabolism, 2012
- Reduction ofNω-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC)Biochemical Journal, 2010
- The Fourth Molybdenum Containing Enzyme mARC: Cloning and Involvement in the Activation ofN-Hydroxylated ProdrugsJournal of Medicinal Chemistry, 2008
- Lysophospholipid Acyltransferases and Arachidonate Recycling in Human NeutrophilsJournal of Biological Chemistry, 2008
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005